Trial Profile
An Observational, Prospective Cohort Study Applying Therapeutic Drug Monitoring (TDM) as an Objective Tool in the Switch from Infliximab Innovator to Biosimilar in Rheumatic Patients
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 31 Jul 2018
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Ankylosing spondylitis; Polyarthritis; Psoriasis; Psoriatic arthritis; Rheumatic disorders; Rheumatoid arthritis; Spondylarthritis
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 31 Jul 2018 New trial record